text
"['\n1. 요약재무정보\n하기 연결재무정보 및 재무정보는 한국채택국제회계기준에 따라 작성되었으며,제61기(전전기)는 종전 기준서인 K-IFRS 1017호에 따라 작성 되었습니다.\n1) 요약연결재무정보\n국제약품(주) 및 종속기업\xa0 \xa0\n(단위 : 원)\n구 분\n제63기 3분기\n제62기\n제61기\n[유동자산]\n55,035,965,427\n61,135,035,867\xa0\n54,559,369,036\n-현금및현금성자산\n2,989,880,972\n7,448,034,125\xa0\n3,658,579,316\n-매출채권\n21,989,942,646\n20,667,104,826\xa0\n24,356,918,543\n-재고자산\n23,268,036,737\n16,595,366,817\xa0\n14,183,645,117\n-기타유동자산\n6,788,105,072\n16,424,530,099\xa0\n12,360,226,060\n[비유동자산]\n96,151,079,733\xa0\n73,458,578,230\xa0\n71,675,526,598\xa0\n-유형자산\n83,795,478,083\xa0\n64,359,978,411\xa0\n61,277,407,372\xa0\n-무형자산\n1,514,543,722\xa0\n1,677,484,748\xa0\n1,872,761,740\xa0\n-투자부동산\n3,984,376,224\xa0\n4,093,469,130\xa0\n4,238,926,338\xa0\n-기타비유동자산\n6,856,681,704\xa0\n3,327,645,941\xa0\n4,286,431,148\xa0\n자산총계\n151,187,045,160\xa0\n134,593,614,097\xa0\n126,234,895,634\xa0\n[유동부채]\n54,343,750,109\xa0\n59,250,771,507\xa0\n48,199,751,500\xa0\n[비유동부채]\n21,451,193,001\xa0\n14,388,889,463\xa0\n9,336,991,512\xa0\n부채총계\n75,794,943,110\xa0\n73,639,660,970\xa0\n57,536,743,012\xa0\n[자본금]\n18,400,520,000\xa0\n18,400,520,000\xa0\n18,057,107,000\xa0\n[주식발행초과금]\n3,871,568,192\xa0\n3,871,568,192\xa0\n3,871,568,192\xa0\n[기타포괄손익누계액]\n30,150,982,986\xa0\n21,480,876,507\xa0\n22,177,699,694\xa0\n[기타자본항목]\n15,816,353,383\xa0\n16,683,166,546\xa0\n16,695,392,877\xa0\n[이익잉여금]\n7,133,421,326\xa0\n492,983,140\xa0\n7,870,638,339\xa0\n지배기업소유주지분\n75,372,845,887\xa0\n60,929,114,385\xa0\n68,672,406,102\xa0\n비지배지분\n19,256,163\xa0\n24,838,742\xa0\n25,746,520\xa0\n자본총계\n75,392,102,050\xa0\n60,953,953,127\xa0\n68,698,152,622\xa0\n부채와자본총계\n151,187,045,160\xa0\n134,593,614,097\xa0\n126,234,895,634\xa0\n매출액\n102,149,410,210\xa0\n111,121,601,008\xa0\n107,681,163,418\xa0\n영업이익\n8,548,807,998\xa0\n5,570,756,961\xa0\n3,287,017,509\xa0\n당기순이익(손실)\n5,865,076,594\xa0\n(4,761,811,946)\n2,182,873,368\xa0\n\xa01.지배기업소유주지분\n5,870,659,173\xa0\n(4,760,904,168)\n2,192,621,154\xa0\n\xa02.비지배지분\n(5,582,579)\n(907,778)\n(9,747,786)\n기타포괄손익\n8,573,072,329\xa0\n(2,384,442,638)\n(558,114,444)\n당기총포괄이익(손실)\n14,438,148,923\xa0\n(7,146,254,584)\n1,624,758,924\xa0\n\xa01.지배기업소유주지분\n14,443,731,502\xa0\n(7,145,346,806)\n1,634,506,710\xa0\n\xa02.비지배지분\n(5,582,579)\n(907,778)\n(9,747,786)\n주당순이익(손실)\n335\xa0\n(272)\n125\n연결에 포함된 회사수\n1\xa0\n1\n1\n<종속기업 재무정보 요약>\n(2020년 3분기)\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0\n\xa0(단위:천원)\n회사명\n총자산\n자기자본\n매출액\n당기순손익\n케이제이케어(주)\n1,673,844\n361,053\n3,025,184\n(104,673)\n(2019년)\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0\n\xa0(단위:천원)\n회사명\n총자산\n자기자본\n매출액\n당기순손익\n케이제이케어(주)\n1,510,709\n465,726\n2,429,926\n(17,021)\n(2018년)\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0\n\xa0(단위:천원)\n회사명\n총자산\n자기자본\n매출액\n당기순손익\n케이제이케어(주)\n1,171,994\n482,747\n1,533,821\n(182,771)\n2) 요약재무정보\n국제약품(주)\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0\n(단위 : 원)\n구 분\n제63기 3분기\n제62기\n제61기\n[유동자산]\n54,217,611,614\xa0\n60,161,878,936\xa0\n53,591,579,999\xa0\n-현금및현금성자산\n2,736,589,009\xa0\n7,218,053,324\xa0\n3,343,108,063\xa0\n-매출채권\n21,550,539,155\xa0\n20,233,344,301\xa0\n24,069,101,895\xa0\n-재고자산\n23,144,159,153\xa0\n16,296,426,007\xa0\n13,837,452,079\xa0\n-기타유동자산\n6,786,324,297\xa0\n16,414,055,304\xa0\n12,341,917,962\xa0\n[비유동자산]\n95,400,244,462\xa0\n72,940,313,200\xa0\n71,518,152,473\xa0\n-유형자산\n83,611,514,088\xa0\n64,214,202,193\xa0\n61,144,981,394\xa0\n-무형자산\n1,511,370,283\xa0\n1,674,311,309\xa0\n1,869,588,301\xa0\n-투자부동산\n3,984,376,224\xa0\n4,093,469,130\xa0\n4,238,926,338\xa0\n-기타비유동자산\n6,292,983,867\xa0\n2,958,330,568\xa0\n4,264,656,440\xa0\n자산총계\n149,617,856,076\xa0\n133,102,192,136\xa0\n125,109,732,472\xa0\n[유동부채]\n54,156,486,368\xa0\n59,080,611,261\xa0\n48,116,428,802\xa0\n[비유동부채]\n21,127,656,618\xa0\n14,278,918,866\xa0\n9,281,215,987\xa0\n부채총계\n75,284,142,986\xa0\n73,359,530,127\xa0\n57,397,644,789\xa0\n[자본금]\n18,400,520,000\xa0\n18,400,520,000\xa0\n18,057,107,000\xa0\n[주식발행초과금]\n3,871,568,192\xa0\n3,871,568,192\xa0\n3,871,568,192\xa0\n[기타포괄손익누계액]\n30,150,982,986\xa0\n21,480,876,507\xa0\n22,177,699,694\xa0\n[기타자본항목]\n15,989,697,310\xa0\n16,856,510,473\xa0\n16,868,736,804\xa0\n[이익잉여금]\n5,920,944,602\xa0\n(866,813,163)\n6,736,975,993\xa0\n자본총계\n74,333,713,090\xa0\n59,742,662,009\xa0\n67,712,087,683\xa0\n자본과부채총계\n149,617,856,076\xa0\n133,102,192,136\xa0\n125,109,732,472\xa0\n종속·관계·공동기업\n투자주식의 평가방법\n원가법\n원가법\n원가법\n매출액\n99,200,295,139\xa0\n108,709,297,057\xa0\n106,305,202,738\xa0\n영업이익\n8,647,619,790\xa0\n5,594,782,551\xa0\n2,978,856,968\xa0\n당기순이익(손실)\n6,017,978,752\xa0\n(4,987,038,125)\n1,698,290,969\xa0\n기타포괄손익\n8,573,072,329\xa0\n(2,384,442,638)\n(558,114,444)\xa0\n당기총포괄손익\n14,591,051,081\xa0\n(7,371,480,763)\n1,140,176,525\xa0\n주당순이익(손실)\n344\xa0\n(285)\n97\n']"
